Lipella Pharmaceuticals (NASDAQ:LIPO) Releases Earnings Results

Lipella Pharmaceuticals (NASDAQ:LIPO) issued its quarterly earnings results on Thursday. The company reported ($1.19) earnings per share (EPS) for the quarter, Zacks reports. Lipella Pharmaceuticals had a negative return on equity of 192.33% and a negative net margin of 882.82%. The business had revenue of $0.17 million during the quarter.

Lipella Pharmaceuticals Stock Performance

Shares of NASDAQ LIPO opened at $2.59 on Friday. The company has a 50 day simple moving average of $2.89 and a two-hundred day simple moving average of $3.03. Lipella Pharmaceuticals has a fifty-two week low of $2.02 and a fifty-two week high of $12.00. The company has a market capitalization of $3.13 million, a price-to-earnings ratio of -0.61 and a beta of 0.13.

About Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).